Literature DB >> 14983975

Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids.

Clifford J Woolf1, Maliha Hashmi.   

Abstract

Medicinal opiates can produce both analgesia and euphoria. The mood altering action of this class of drugs has led to their abuse (non-medical use), a problem compounded by their physical dependence and addictive qualities. The legitimate expansion of clinical opioid analgesic use for severe chronic non-malignant pain, together with the introduction of high-dose extended-release (modified-release) oral tablet formulations of opioids with good bioavailability, has created increased opportunities for the illicit use of these prescribed drugs. Such use is now a major societal problem, with an incidence that appears to exceed the use of street narcotics such as heroin in the US. This review highlights the extent of the illicit use of prescribed opiate analgesics and some of the steps, legal, educational and pharmaceutical, that can be taken to potentially reduce the risk of their misuse or diversion for abuse.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14983975

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  20 in total

1.  Signaling cascades for δ-opioid receptor-mediated inhibition of GABA synaptic transmission and behavioral antinociception.

Authors:  Zhi Zhang; Zhizhong Z Pan
Journal:  Mol Pharmacol       Date:  2011-12-05       Impact factor: 4.436

2.  Web-based instruction on substance abuse and drug diversion.

Authors:  Jennifer Reinhold; Laura Pontiggia; Mark Angeles; Grace Earl
Journal:  Am J Pharm Educ       Date:  2010-05-12       Impact factor: 2.047

3.  Persistent pain facilitates response to morphine reward by downregulation of central amygdala GABAergic function.

Authors:  Zhi Zhang; Wenjuan Tao; Yuan-Yuan Hou; Wei Wang; Yun-Gang Lu; Zhizhong Z Pan
Journal:  Neuropsychopharmacology       Date:  2014-04-01       Impact factor: 7.853

4.  Rewarding morphine-induced synaptic function of delta-opioid receptors on central glutamate synapses.

Authors:  Bihua Bie; Wei Zhu; Zhizhong Z Pan
Journal:  J Pharmacol Exp Ther       Date:  2009-01-23       Impact factor: 4.030

Review 5.  Issues in long-term opioid therapy: unmet needs, risks, and solutions.

Authors:  Steven D Passik
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

Review 6.  Abuse-deterrent opioid formulations: are they a pipe dream?

Authors:  Nathaniel Katz
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

7.  Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.

Authors:  Joseph Stauffer; Beatrice Setnik; Marta Sokolowska; Myroslava Romach; Franklin Johnson; Edward Sellers
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

8.  Synaptic mechanism for functional synergism between delta- and mu-opioid receptors.

Authors:  Zhi Zhang; Zhizhong Z Pan
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

9.  Route of administration for illicit prescription opioids: a comparison of rural and urban drug users.

Authors:  April M Young; Jennifer R Havens; Carl G Leukefeld
Journal:  Harm Reduct J       Date:  2010-10-15

10.  MeCP2 repression of G9a in regulation of pain and morphine reward.

Authors:  Zhi Zhang; Wenjuan Tao; Yuan-Yuan Hou; Wei Wang; Paul J Kenny; Zhizhong Z Pan
Journal:  J Neurosci       Date:  2014-07-02       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.